NASDAQ: KAKineta Inc Stock
$3.21-2.14 (-40%)
Updated Mar 17, 2023
KA Price
$3.21
Fair Value Price
$5.49
Market Cap
$4.98M
52 Week Low
$3.21
52 Week High
$17.43
P/E
-0.15x
P/B
0.91x
P/S
3.52x
PEG
N/A
Dividend Yield
311.84%
Revenue
$4.84M
Earnings
-$32.00M
Gross Margin
100%
Operating Margin
-647.61%
Profit Margin
-660.6%
Debt to Equity
0.75
Operating Cash Flow
-$26M
Beta
0.64
Next Earnings
Mar 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A
KA Overview
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KA ($3.21) is undervalued by 41.56% relative to our estimate of its Fair Value price of $5.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KA ($3.21) is significantly undervalued by 41.56% relative to our estimate of its Fair Value price of $5.49 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more KA due diligence checks available for Premium users.
Be the first to know about important KA news, forecast changes, insider trades & much more!
KA News
Valuation
KA fair value
Fair Value of KA stock based on Discounted Cash Flow (DCF)
Price
$3.21
Fair Value
$5.49
Undervalued by
41.56%
KA ($3.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KA ($3.21) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
16.18x
Market
21.81x
KA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
4.75x
KA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KA's financial health
Profit margin
Revenue
$1.4M
Net Income
-$3.4M
Profit Margin
-239.9%
KA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.6M
Liabilities
$4.1M
Debt to equity
0.75
KA's short-term assets ($9.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KA's short-term assets ($9.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
$0.0
Financing
-$578.0k
KA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KA vs Biotech Stocks
Kineta Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.